养肝益水颗粒对原发性高血压早期肾损害的有效性及对炎症因子影响的临床观察

发布时间：2018-01-01 11:04

  本文关键词：养肝益水颗粒对原发性高血压早期肾损害的有效性及对炎症因子影响的临床观察　出处：《安徽中医药大学》2016年硕士论文　论文类型：学位论文

  更多相关文章： 养肝益水颗粒 高血压早期肾损害 临床观察 炎症因子

【摘要】：目的:观察养肝益水颗粒对原发性高血压早期肾损害患者的疗效及对相关炎症因子的影响,并探讨其作用机制,为养肝益水颗粒防治高血压早期肾损害提供临床依据。方法:病例选择西医确诊为原发性高血压早期肾损害,中医辨证属肝肾阴虚或兼夹血瘀证的患者50例,采用随机、对照的方法,随机分为治疗组和对照组,每组均为25例。两组均给予生活方式干预、西医常规降压等治疗,治疗组在对照组的基础上加用养肝益水颗粒。两组疗程均为6周。疗程结束后观察两组患者的中医证候积分、尿白蛋白/肌酐、尿α1微球蛋白(al-MG)、尿微量白蛋白(m Al B)、尿转铁蛋白(TRF)、尿免疫球蛋白G(Ig GU)及尿β2微球蛋白(β2-MG)、超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)、细胞间黏附分子-1(ICAM-1)及胱抑素C(Cys-C)等变化情况。结果:1.治疗前两组基线数据(年龄、性别、尿白蛋白/肌酐、尿微量蛋白、hs-CRP、IL-6、ICAM-1、Cys-C等)无统计学差异(p0.05);2.治疗后,中医证候积分方面治疗组较对照组下降明显(p0.05);3.治疗后,两组尿五蛋白及UACR均有不同程度的下降(p0.05或p0.01),但对照组的Ig GU、TRF及UACR下降无统计学意义;治疗组的尿五蛋白下降较对照组更为显著(p0.05或p0.01);4.治疗后,两组hs-CRP、IL-6均有所下降(p0.05),但治疗组优于对照组(p0.05)。5.治疗后两组ICAM-1及Cys-C均有所下降,但只有治疗组的Cys-C下降具有统计学意义(p0.05)。结论:养肝益水颗粒能有效改善高血压早期肾损害患者的临床伴随症状且安全性高,可有效降低患者尿微量蛋白、抑制hs-CRP、IL-6及Cys-C等相关炎症因子的释放。初步证实养肝益水颗粒可能是通过抑制炎症因子释放,减轻肾脏细胞炎症反应,从而延缓肾损害进程、保护肾脏功能。
[Abstract]:Objective: To observe the curative effect of YangGanYiShui Granule on primary hypertension patients with early renal damage and effects on inflammatory factors, and explore its mechanism, to provide clinical basis for early renal damage of YangGanYiShui Granule on prevention and treatment of hypertension. Methods: patients diagnosed with western medicine on early renal damage in hypertensive patients, TCM. 50 cases of patients with liver and kidney deficiency and blood stasis syndrome or using a randomized control method, were randomly divided into treatment group and control group, each group had 25 cases. The two groups were given lifestyle intervention, blood pressure and other conventional western medicine treatment, the treatment group in the control group based on the use of YangGanYiShui granule. Two groups were treated for 6 weeks. To observe the TCM syndrome integral of two groups of patients after treatment, urinary albumin / creatinine, urine alpha 1 microglobulin (al-MG), urinary albumin (m Al B), urinary transferrin (TRF), urinary immunoglobulin G (Ig GU) and urinary beta 2 寰�鐞冭泲鐧�(尾2-MG),瓒呮晱C鍙嶅簲铔嬬櫧(hs-CRP),鐧戒粙绱，

本文编号：1364213